Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Idiopathic macular hole.

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Retina/Vitreous Panel, Preferred Practice Patterns Committee. Idiopathic macular hole. San Francisco (CA): American Academy of Ophthalmology (AAO); 2008. 20 p. [151 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology Retina Panel, Preferred Practice Patterns Committee. Idiopathic macular hole. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 17 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the "approved by" date unless superseded by a revision.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The ratings of importance to the care process (A-C) and the ratings for strength of evidence (I-III) are defined at the end of the "Major Recommendations" field.

Diagnosis

The initial evaluation of a patient with symptoms and signs suggestive of macular hole includes all features of the comprehensive adult medical eye evaluation, with particular attention to those aspects relevant to macular hole (American Academy of Ophthalmology Preferred Practice Patterns Committee, 2005). Conditions often mistaken for the various stages of macular hole include cystoid macular edema, central serous retinopathy, a subfoveolar druse, lamellar macular hole, epiretinal membrane with pseudohole, and solar maculopathy (Ho, Guyer, & Fine, 1998; Gass & Joondeph, 1990; Smiddy & Gass, 1995).

History

In general, a complete history includes the following items, although the exact composition varies with the patient's particular problems and needs.

  • Duration of symptoms [A:III]
  • Ocular history: glaucoma or other prior eye diseases, injuries, surgery, or other treatments, prolonged gazing at the sun [A:III]
  • Medications that may be related to macular cysts (e.g., systemic niacin, topical prostaglandin analogues) [A:III]

Examination

  • Slit-lamp biomicroscopy of the macula and the vitreoretinal interface [A:III]

Management

Management Recommendations for Macular Hole

Stage Management Follow-up [A:II]
1-A Observation (de Bustros,1994) [A:II]
  • Prompt return if new symptoms
  • Every 4 to 6 months in the absence of symptoms
1-B Observation (de Bustros,1994) [A:II]
  • Prompt return if new symptoms
  • Every 4 to 6 months in the absence of symptoms
2 Surgery (Kim et al.,1996) [A:II]*
  • 1 to 2 days postoperatively, then 1 to 2 weeks
  • Frequency and timing of subsequent visits varies depending on the outcome of surgery and the patient's symptoms
  • If no surgery, every 4 to 8 months
3 Surgery (Kim et al.,1996; Freeman et al., 1997) [A:I]
  • 1 to 2 days postoperatively, then 1 to 2 weeks
  • Frequency and timing of subsequent visits varies depending on the outcome of surgery and the patient's symptoms
4 Surgery (Kim et al., 1996; Freeman et al., 1997) [A:I]
  • 1 to 2 days postoperatively, then 1 to 2 weeks
  • Frequency and timing of subsequent visits varies depending on the outcome of surgery and the patient's symptoms

*Although surgery is usually performed, observation is also appropriate.

The surgeon should inform the patient of the relative risks, benefits, and alternatives to surgery (American Academy of Ophthalmology, "Pretreatment Assessment," 2006; American Academy of Ophthalmology, " An Ophthalmologist's Duties," 2006), and, in particular, of the need for use of intraocular gas or special patient positioning postoperatively. [A:III] Patients with glaucoma should be informed of the possibility of a perioperative increase in intraocular pressure. [A:III] The surgeon is responsible for formulating a postoperative care plan and should inform the patient of these arrangements (American Academy of Ophthalmology, "Pretreatment Assessment," 2006; American Academy of Ophthalmology, "An Ophthalmologist's Duties," 2006). [A:III]

Follow-Up

Components of the follow-up examination should include the following:

  • Interval history, including new symptoms [A:III]
  • Measurement of intraocular pressure [A:III]
  • Slit-lamp biomicroscopy of the retina and indirect binocular ophthalmoscopy to evaluate the peripheral retina [A:III]

Optical coherence tomography is helpful to document the macular anatomy.

Patients who have had a macular hole in one eye should be informed that there is a 10% to 15% chance over a period of 5 years of macular hole formation in the fellow eye if no posterior vitreous detachment is present and a 2% chance if posterior vitreous detachment is present (Ezra et al., 1998; Akiba, Quiroz, & Trempe, 1990; Lewis et al., 1996; Fisher et al., 1994; Guyer et al., 1992; Chew et al., 1999). [A:III]

Counseling/Referral

Patients should be informed to notify their ophthalmologist promptly if they have symptoms such as an increase in floaters, a loss of visual field, or a decrease in visual acuity (Dayan et al., 1996; Byer, 1994; Smiddy et al., 1989). [A:II] Patients should be informed that air travel, high altitudes, or general anesthesia with nitrous oxide should be avoided until the gas tamponade is nearly completely gone. [A:III] Vision rehabilitation restores functional ability (Stelmack et al., 2008) [A:I] and patients with functionally limiting postoperative visual impairment should be referred for vision rehabilitation and social services (American Academy of Ophthalmology Vision Rehabilitation Committee, 2007). [A:III] More information on vision rehabilitation, including materials for patients, is available at http://www.aao.org/smartsight.

Definitions:

Ratings of Importance to Care Process

Level A, defined as most important
Level B, defined as moderately important
Level C, defined as relevant but not critical

Ratings of Strength of Evidence

Level I includes evidence obtained from at least one properly conducted, well-designed randomized, controlled trial. It could include meta-analyses of randomized controlled trials.

Level II includes evidence obtained from the following:

  • Well-designed controlled trials without randomization
  • Well-designed cohort or case-control analytic studies, preferably from more than one center
  • Multiple-time series with or without the intervention

Level III includes evidence obtained from one of the following:

  • Descriptive studies
  • Case reports
  • Reports of expert committees/organization (e.g., Preferred Practice Patterns [PPP] panel consensus with external peer review)

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for most recommendations (see "Major Recommendations" field).

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • American Academy of Ophthalmology Retina/Vitreous Panel, Preferred Practice Patterns Committee. Idiopathic macular hole. San Francisco (CA): American Academy of Ophthalmology (AAO); 2008. 20 p. [151 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2003 (revised 2008 Sep)

GUIDELINE DEVELOPER(S)

American Academy of Ophthalmology - Medical Specialty Society

SOURCE(S) OF FUNDING

American Academy of Ophthalmology without commercial support

GUIDELINE COMMITTEE

Retina/Vitreous Panel; Preferred Practice Patterns Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Members of the Retina/Vitreous Panel: Emily Y. Chew, MD, Chair, Macula Society and Retina Society Representative; William E. Benson, MD; Barbara A. Blodi, MD; H. Culver Boldt, MD; Timothy G. Murray, MD, Consultant and American Society of Retina Specialists Representative; Timothy W. Olsen, MD; Carl D. Regillo, MD, FACS; Ingrid U. Scott, MD, MPH; Leslie Hyman, PhD, Methodologist

Members of the Preferred Practice Patterns Committee: Sid Mandelbaum, MD, Chair; Emily Y. Chew, MD; Linda M. Christmann, MD; Douglas E. Gaasterland, MD; Samuel Masket, MD; Stephen D. McLeod, MD; Christopher J. Rapuano, MD; Donald S. Fong, MD, MPH, Methodologist

Academy Staff: Flora C. Lum, MD; Nancy Collins, RN, MPH; Doris Mizuiri

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

These panel and committee members have disclosed the following financial relationships occurring from January 2007 to October 2008:

H. Culver Boldt, MD: Alcon Laboratories, Inc. – Consultant/Advisor

Donald S. Fong, MD, MPH: Merck – Consultant/Advisor

Douglas E. Gaasterland, MD: Inspire Pharmaceuticals – Consultant/Advisor; IRIDEX – Consultant/Advisor, Equity owner, Patents/Royalty

Samuel Masket, MD: Alcon Laboratories, Inc. – Consultant/Advisor, Lecture fees, Grant support; Allergan, Inc. – Lecture fees; Bausch & Lomb, Inc. – Lecture fees; Omeros Pharmaceuticals, Inc. – Consultant/Advisor; Othera Pharmaceuticals, Inc. – Consultant/Advisor; PowerVision – Consultant/Advisor; Visiogen, Inc. – Consultant/Advisor

Stephen D. McLeod, MD: Alcon Laboratories, Inc. – Consultant/Advisor, Grant support; InSite Vision, Inc. – Consultant/Advisor, Visiogen, Inc. – Consultant/Advisor, Equity owner, Grant support

Timothy W. Olsen, MD: iScience – Grant support; Powerscope, Inc. – Grant support

Christopher J. Rapuano, MD: Alcon Laboratories, Inc. – Lecture fees; Allergan, Inc. – Consultant/Advisor, Lecture fees; Inspire Pharmaceuticals – Lecture fees; Ista Pharmaceuticals – Lecture fees; Rapid Pathogen Screening – Equity/owner; Ziemer Ophthalmic Systems AG – Consultant/Advisor

Carl D. Regillo, MD, FACS: Alcon Laboratories, Inc. – Consultant/Advisor; Eyetech, Inc. – Consultant/Advisor, Grant support; Genentech, Inc. – Consultant/Advisor, Grant support; Novartis – Consultant/Advisor, Grant support; QLT Phototherapeutics, Inc. – Consultant/Advisor, Grant support

Ingrid U. Scott, MD, MPH: Eyetech, Inc. – Consultant/Advisor, Lecture fees; Genentech, Inc. – Consultant/Advisor, Lecture fees; Pfizer Ophthalmics – Consultant/Advisor, Lecture fees

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: American Academy of Ophthalmology Retina Panel, Preferred Practice Patterns Committee. Idiopathic macular hole. San Francisco (CA): American Academy of Ophthalmology (AAO); 2003. 17 p.

All Preferred Practice Patterns are reviewed by their parent panel annually or earlier if developments warrant and updated accordingly. To ensure that all Preferred Practice Patterns are current, each is valid for 5 years from the "approved by" date unless superseded by a revision.

GUIDELINE AVAILABILITY

Electronic copies: Available from the American Academy of Ophthalmology (AAO) Web site.

Print copies: Available from American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424; Phone: (415) 561-8540.

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on April 30, 2004. The information was verified by the guideline developer May 20, 2004. This NGC summary was updated by ECRI Institute on April 22, 2009. The updated information was verified by the guideline developer on May 15, 2009.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Information about the content, ordering, and copyright permissions can be obtained by calling the American Academy of Ophthalmology at (415) 561-8500.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo